
Opinion|Videos|June 21, 2024
Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape
Key opinion leaders provide a concise overview of the atopic dermatitis (AD) treatment landscape, focusing on the role of topical therapy, and highlight the current unmet needs in AD management.
Advertisement
Episodes in this series

- Provide a brief overview of the treatment landscape, and where topical therapies and systemic therapies fit into this landscape. What are the current unmet needs from your perspective?
- Please incorporate a discussion of the following topical therapies:
- Corticosteroids
- Crisaborole – AD-301/AD-302 ,CrisADe CARE 1 
- Ruxolitinib – TRuE-AD1/TRuE-AD2 – original publication ,long-term follow up 
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC
3
New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access
4
Measles Outbreaks Cause Financial, Public Health Burden in US
5














































